Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New cholesterol guidelines, new treatment challenges.

James M McKenney1

  • 1National Clinical Research, Inc, Richmond, VA, USA. jmckenney@ncrinc.net

Pharmacotherapy
|July 20, 2002
PubMed
Summary

New guidelines increase the number of patients needing lipid-lowering therapy for coronary heart disease (CHD). Achieving low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) goals presents a challenge for clinicians.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.

Journal of clinical lipidology·2021
Same author

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.

Journal of clinical lipidology·2020
Same author

Alirocumab in high-risk patients: Observations from the open-label expanded use program.

Journal of clinical lipidology·2018
Same author

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).

The American journal of cardiology·2017
Same author

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.

Journal of clinical lipidology·2016
Same author

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.

The American journal of cardiology·2016

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Coronary heart disease (CHD) is a leading cause of death in Americans.
  • Low-density lipoprotein cholesterol (LDL) levels directly correlate with CHD events.
  • Current lipid-lowering therapy achieves goal LDL levels in only about 18% of patients.

Purpose of the Study:

  • To address the challenge clinicians face in achieving new LDL and non-HDL goals.
  • To review current and emerging therapies for lipid management in high-risk patients.
  • To inform strategies for improving treatment adherence and outcomes.

Main Methods:

  • Review of existing epidemiologic and clinical trial data on lipid-lowering therapies.
  • Analysis of new National Cholesterol Education Program guidelines and their impact.
  • Discussion of current pharmacologic options including statins, bile acid resins, niacin, fibrates, and fish oils.
  • Overview of novel drug classes under development, such as super statins, cholesterol absorption inhibitors, and dual PPAR agonists.

Main Results:

  • New guidelines expand eligibility for lipid-altering drugs to 36 million Americans.
  • Statins are highly effective for lowering LDL and non-HDL cholesterol.
  • Combination therapy or novel agents may be required when statin monotherapy is insufficient.

Conclusions:

  • Achieving lipid goals is crucial for reducing CHD risk in a larger patient population.
  • Clinicians must employ effective strategies, including combination therapy and new drug classes, to meet treatment targets.
  • Ongoing research into novel lipid-lowering agents promises improved therapeutic options.

Related Experiment Videos